natgillin/translations-raw huggingface dataset:
Calciumtilskud, antacida samt visse orale lægemidler indeholdende multivalente kationer Calciumtilskud, antacida samt visse orale lægemidler indeholdende multivalente kationer (som f.eks. aluminium, magnesium, jern) vil sandsynligvis påvirke absorptionen af Ibandronsyre Teva.
Calcium supplements, antacids and some oral medicinal products containing multivalent cations Calcium supplements, antacids and some oral medicinal products containing multivalent cations (such as aluminium, magnesium, iron) are likely to interfere with the absorption of Ibandronic Acid Teva.
Calciumtilskud, jerntilskud eller multivitaminer skal tages tidsforskudt fra administrationen af Triumeq (minimum 2 timer efter eller 6 timer før).
Calcium supplements, iron supplements or multivitamins should be taken well separated in time from the administration of Triumeq (minimum 2 hours after or 6 hours before).
Camberley
Camberley Belgium.
Camberley
Frimley
Campus 21, Liebermannstraße A01/501 A-2345 Brunn am Gebirge
Campus 21, Liebermannstraße A01/501 2345 Brunn am Gebirge
Campus Vienna Biocenter 3 A-1030 Wien
Campus Vienna Biocenter 3 A-1030 Vienna
Can Parellada Industrial 08228 Terrassa SPANIEN
Can Parellada Industrial 08228 Terrassa
CANADE 3C-5 (stamme 1895)) ved hjælp af rekombinant DNA-teknologi.
CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
CANADE 3C-5 (stamme 1895)) vha. rekombinant DNA-teknologi.
CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
CANADE 3G-5 (stamme 1895)) ved hjælp af rekombinant DNA-teknologi.
CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
Canagliflozin + insulin
Canagliflozin + metformin
Canagliflozin + metformin og sulfonylurinstof
Canagliflozin + insulin
Canagliflozin + metformin og sulfonylurinstof
Canagliflozin + metformin and sulphonylurea
Canagliflozin 300 mg + metformin og sulfonylurinstof (N=377)
Canagliflozin 300 mg + metformin and sulphonylurea (N = 377)
Canagliflozin blev sammenlignet med glimepirid som dobbeltbehandling med metformin, og det blev sammenlignet med sitagliptin som trippelbehandling med metformin og sulfonylurinstof (tabel 3).
Compared to sitagliptin as triple therapy with metformin and sulphonylurea (52 weeks)
Canagliflozin bør ikke initieres hos patienter med eGFR < 60 ml/min/1,73 m2 eller CrCl < 60 ml/min.
Canagliflozin should not be initiated in patients with an eGFR < 60 mL/min/1.73 m2 or CrCl < 60 mL/min.
Canagliflozin bør seponeres ved vedvarende eGFR
Canagliflozin should be discontinued when eGFR is persistently below
Canagliflozin metaboliseres primært via glucuronidkonjugering udvirket af UDP-glucuronosyl- transferase 1A9 (UGT1A9) og 2B4 (UGT2B4).
The metabolism of canagliflozin is primarily via glucuronide conjugation mediated by UDP glucuronosyl transferase 1A9 (UGT1A9) and 2B4 (UGT2B4).
Canagliflozin metaboliseres primært via glukuronidkonjugering medieret af UDP-glukuronyl- transferase 1A9 (UGT1A9) og 2B4 (UGT2B4).
The metabolism of canagliflozin is primarily via glucuronide conjugation mediated by UDP glucuronosyl transferase 1A9 (UGT1A9) and 2B4 (UGT2B4).
Canagliflozin skal straks seponeres ved mistænkt eller verificeret DKA.
In patients where DKA is suspected or diagnosed, treatment with canagliflozin should be discontinued immediately.
Canagliflozin udviser ikke tidsafhængig farmakokinetik, og op til 36 % akkumuleres i plasma efter gentagne doser på 100 mg eller 300 mg.
Canagliflozin does not exhibit time-dependent pharmacokinetics, and accumulated in plasma up to 36% following multiple doses of 100 mg and 300 mg.
Canagliflozin udviser ikke tidsafhængig farmakokinetik, og op til 36 % akkumuleres i plasma efter gentagne doser på 100 mg og 300 mg.
Canagliflozin does not exhibit time-dependent pharmacokinetics, and accumulated in plasma up to 36% following multiple doses of 100 mg and 300 mg.
Canagliflozin virker ved at blokere proteinet natrium-glukose-kotransportør 2 (SGLT2) i nyrerne.
canagliflozin works by blocking a protein in the kidneys called sodium glucose co-transporter 2 (SGLT2).
canagliflozin/metforminhydrochlorid
canagliflozin/metformin hydrochloride
Canagliflozins indvirkning på andre lægemidler Digoxin
Effects of canagliflozin on other medicinal products Digoxin
Canagliflozins virkningsmekanisme med øgning af UGE og derigennem sænkning af plasmaglucose er uafhængig af insulin.
Canagliflozin’s action to increase UGE directly lowering plasma glucose is independent of insulin.
Canagliflozins virkningsmekanisme med øgning af UGE og derigennem sænkning af plasmaglucose påvirkes ikke af insulin.
Canagliflozin’s action to increase UGE directly lowering plasma glucose is independent of insulin.
Canakinumab er et rent humant monoklonalt anti-human interleukin-1 beta (IL-1 beta)-antistof af
Canakinumab is a fully human monoclonal anti-human interleukin-1 beta (IL-1 beta) antibody of the
Canakinumab er udviklet til at binde sig til receptoren for et signalmolekyle eller et "cytokin" i kroppen kaldet interleukin-1 beta.
Canakinumab has been designed to attach to a messenger molecule or ‘cytokine’ in the body called interleukin-1 beta.
Canarypox virus (vCP97) ≥ 10 7.2 CCID501
Canarypox virus (vCP97) ≥ 10 7.2
Canarypoxvirus spredes ikke og opformeres ikke i katten, men producerer proteiner fra FeLV- generne.
The canarypox viruses do not spread or multiply in the cat but they do produce proteins from the FeLV genes.
Cancer blev rapporteret hos behandlingserfarne og behandlingsnaive patienter, som startede i behandling med ISENTRESS sammen med andre antiretrovirale lægemidler.
Cancers were reported in treatment-experienced and treatment-naïve patients who initiated ISENTRESS in conjunction with other antiretroviral agents.
Cancer i galdegange, diffust storcellet B-celle lymfom, Hodgkins sygdom, knoglemetastaser, levermetastaser, metastaser i peritoneum, kræft i næsesvælget, øsofagal karcinom
Bile duct cancer, diffuse large B-cell lymphoma, Hodgkin’s disease, metastases to bone, metastases to liver, metastases to peritoneum, nasopharyngeal cancer, oesophageal carcinoma
Cancer i lymfesystemet (lymfom)
Cancer of the lymphatic system (lymphoma)
cancer i parathyroidea, primær HPT hos patienter, hvor der ville være indikation for parathyroidektomi på grundlag af serumkalciumniveauerne (som angivet i relevante behandlingsretningslinjer), men hos hvem parathyroidektomi ikke er klinisk mulig eller kontraindiceret.
parathyroid carcinoma. primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
Cancer i paratyroidea og primær hyperparatyroidisme:
Parathyroid carcinoma and primary hyperparathyroidism:
cancer i paratyroidea, primær HPT hos patienter, hvor der ville være indikation for paratyroidektomi på grundlag af serumcalciumniveauerne (som angivet i relevante behandlingsretningslinjer), men hos hvem paratyroidektomi ikke er klinisk mulig eller er kontraindiceret.
parathyroid carcinoma. primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
Cancer patienter
Cancer patients
Cancer, følgesygdomme (f.eks. anæmi, koagulationslidelse, infektion), rygning.
Cancer, co morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
Cancer, komorbide tilstande (fx anæmi, koagulopatier, infektion), rygning.
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking
cancer, komorbide tilstande (fx anæmi, koagulopatier, infektion), rygning.
cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
Cancer, systemisk lupus erythematosus, hæmolytisk uræmisk syndrom, kronisk inflammatorisk tarmsygdom (Crohn's sygdom eller ulcerativ colitis) og seglcelleanæmi
Cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) and sickle cell disease
Cancerpatienter blodprop (trombotiske vaskulære hændelser) (se afsnittet “Advarsler og forsigtighedsregler”). forhøjet blodtryk.
Cancer patients blood clotting (thrombotic vascular events) (see section “Warnings and precautions”). increase of blood pressure.
Cancersmerter (G3/4: 0,6%)
Cancer pain (G3/4: 0.6%)
Cancersmerter (G3/4: 1,2 %)
Cancer pain (G3/4: 1.2%)
Cancersmerter (G3/4: 1,2%)
Cancer pain (G3/4: 1.2%)
CANCIDAS 50 mg pulver til koncentrat til infusionsvæske, opløsning
CANCIDAS 50 mg powder for concentrate for solution for infusion
CANCIDAS 50 mg pulver til koncentrat til infusionsvæske, opløsning Caspofungin
CANCIDAS 50 mg powder for concentrate for solution for infusion Caspofungin
CANCIDAS 70 mg pulver til koncentrat til infusionsvæske, opløsning
CANCIDAS 70 mg powder for concentrate for solution for infusion
CANCIDAS 70 mg pulver til koncentrat til infusionsvæske, opløsning Caspofungin
CANCIDAS 70 mg powder for concentrate for solution for infusion Caspofungin
Cancidas anvendes til at behandle følgende infektioner hos børn, unge og voksne: alvorlige svampeinfektioner i væv eller organer (kaldet "invasiv candidiasis").
Cancidas is used to treat the following infections in children, adolescents and adults: serious fungal infections in your tissues or organs (called ‘invasive candidiasis’).
Cancidas er et sterilt, hvidt/brækket hvidt kompakt pulver.
Cancidas is a sterile, white to off-white compact powder.
Cancidas er formuleret mhp. at kunne give den fulde dosis, der er angivet på hætteglassets etiket (50 mg), når 10 ml trækkes op af hætteglasset.
c CANCIDAS is formulated to provide the full labelled vial dose (50 mg) when 10 ml is withdrawn from the vial.
CANCIDAS er formuleret mhp. at kunne give den fulde dosis, der er angivet på hætteglassets etiket (50 mg), når 10 ml trækkes op af hætteglasset.
CANCIDAS is formulated to provide the full labeled vial dose (50 mg) when 10 ml is withdrawn from the vial.
Cancidas er formuleret mhp. at kunne give den fulde dosis, der er angivet på hætteglassets etiket (70 mg), når 10 ml trækkes op af hætteglasset.
c CANCIDAS is formulated to provide the full labelled vial dose (70 mg) when 10 ml is withdrawn from the vial.
CANCIDAS er formuleret mhp. at kunne give den fulde dosis, der er angivet på hætteglassets etiket (70 mg), når 10 ml trækkes op af hætteglasset.
CANCIDAS is formulated to provide the full labelled vial dose (70 mg) when 10 ml is withdrawn from the vial.
Cancidas er ikke undersøgt hos gravide kvinder.
Cancidas has not been studied in pregnant women.
CANCIDAS MÅ IKKE BLANDES ELLER INFUNDERES SAMMEN MED
DO NOT MIX OR CO-INFUSE CANCIDAS WITH ANY OTHER
CANCIDAS) eller et af de øvrige indholdsstoffer i dette lægemiddel (angivet i punkt 6).
CANCIDAS), or any of the other ingredients of this medicine (listed in section 6).
canda.consumer-relations @gsk.com
scanda.consumer-relations @gsk.com
Candida arter
Candida species
Candida arter (herunder fluconazol resistente C. krusei og resistente stammer af C. glabrata og
Candida species (including fluconazole-resistant C. krusei and resistant strains of C. glabrata and
Candidavaginitis
Vaginal candidiasis
Candidiasis (herunder oral og anal candidiasis) og svampeinfektion/svampeinfektion i huden
Candidiasis (including oral and anal candidiasis) and fungal infection/fungal skin infections
Candidiasis i mund og svælg Pneumoni (hos KOL-patienter) Bronkitis
Candidiasis of the mouth and throat Pneumonia (in COPD patients) Bronchitis
Candidiasis i øsofagus: Ved behandling af candidiasis i øsofagus bør Mycamine administreres i mindst en uge, efter at kliniske symptomer er ophørt.
Oesophageal candidiasis: For the treatment of oesophageal candidiasis, Mycamine should be administered for at least one week after resolution of clinical signs and symptoms.
Candidiasis Nasofaryngitis
Candidiasis Nasopharyngitis
candidiasis og oral
candidiasis and
candidiasis)
Oral candidiasis)
Candidiasis, inklusive orofaryngeal og vulvovaginal, Clostridium difficile colitis, urinvejsinfektion (svampe)
Candidiasis including oropharyngeal and vulvovaginal, Clostridium difficile colitis, fungal urinary tract infection
Candidiasis, stafylokokinfektion
candidiasis, staphylococcal infection
Candidæmi og andre former for invasiv candidiasis
Candidaemia and other forms of Invasive Candidiasis
Candidæmi og invasiv Candidiasis: Micafungin (100 mg/dag eller 2 mg/kg/dag) var lige så effektiv og bedre tolereret end liposomalt amphotericin B (3 mg/kg) som førstevalgsbehandling af candidæmi og invasiv candidiasis i et randomiseret, dobbeltblindt, multinationalt non-inferioritetsstudie.
Candidaemia and Invasive Candidiasis: Micafungin (100 mg/day or 2 mg/kg/day) was as effective as and better tolerated than liposomal amphotericin B (3 mg/kg) as first-line treatment of candidaemia and invasive candidiasis in a randomised, double-blind, multinational non-inferiority study.
Cangene-logo indsættes
Cangene Logo to be inserted
Cangrelors gennemsnitlige steady state-koncentration under en konstant intravenøs infusion ved 4 mikrogram/kg/min. er 488 ng/ml.
The mean steady state concentration of cangrelor during a constant intravenous infusion of 4 micrograms/kg/min is 488 ng/mL.
Cangrelors sikkerhed er blevet vurderet hos over 12.700 behandlede patienter, som gennemgår PCI.
The safety of cangrelor has been evaluated in over 12,700 treated patients undergoing PCI.
Canigen L4 Injektionsvæske, suspension til hunde
Canigen L4 Suspension for injection for dogs
Canigen L4, injektionsvæske, suspension til hunde
Canigen L4, suspension for injection for dogs
CaniLeish
Invented
CaniLeish anvendes udelukkende til ‘leishmania-negative’ hunde.
CaniLeish is to be used only in ‘leishmania-negative’ dogs.
CaniLeish er en vaccine, som indeholder en række proteiner, der frigives fra Leishmania infantum- parasitten under dennes vækst.
CaniLeish is a vaccine that contains a number of proteins that are released from the Leishmania infantum parasite during its growth.
CaniLeish indeholder en ‘adjuvans’ (en højkoncentreret del af Quillaja saponaria), som styrker immunresponsen.
CaniLeish contains an ‘adjuvant’ (a highly purified fraction of Quillaja saponaria) to enhance the immune response.
CaniLeish lyofilisat og solvens til injektionsvæske, suspension til hunde.
CaniLeish lyophilisate and solvent for suspension for injection for dogs
Cansancio o palidez.
Tiredness and/or looking pale
Capecetabin kan inducere forekomsten af diarré, hvilket er observeret hos op til 50 % af patienterne.
Capecitabine can induce the occurrence of diarrhoea, which has been observed in up to 50% of patients.
Capecitabin (2.500 mg/ m2/dag, dag 1-14 hver 21. dag)
Capecitabine (2,500 mg/m2/day, days 1-14 q21 days)
Capecitabin (n = 380)
Capecitabine (n = 380)
Capecitabin (n = 83)
Capecitabine (n = 83)
Capecitabin er et "prodrug" (et forstadium), der i kroppen omdannes til 5-fluoruracil (5-FU), men omdannelsen sker i højere grad i svulstcellerne end i normalt væv.
Capecitabine is a ‘prodrug’ that is converted to 5-fluorouracil (5-FU) in the body, but more is converted in tumour cells than in normal tissues.
Capecitabin er et "prodrug" (et forstadium), der omdannes til 5-fluoruracil (5- FU) i kroppen, hovedsageligt i svulstcellerne.
Capecitabine is a ‘prodrug’ that is converted to 5-fluorouracil (5-FU) in the body, mainly in tumour cells.
Capecitabin er et ‘prodrug’ (et forstadium), der i kroppen omdannes til 5- fluoruracil (5-FU), men omdannelsen sker i højere grad i svulstcellerne end i normalt væv.
Capecitabine is a ‘prodrug’ that is converted to 5-fluorouracil (5-FU) in the body, but more is converted in tumour cells than in normal tissues.
Capecitabin er et ‘prodrug’ (et forstadium), der i kroppen omdannes til 5-fluoruracil (5-FU), men omdannelsen sker i højere grad i svulstcellerne end i normalt væv.
Capecitabine is a ‘prodrug’ that is converted to 5-fluorouracil (5-FU) in the body, but more is converted in tumour cells than in normal tissues.
Capecitabin er indiceret som adjuverende behandling af patienter, som er opereret for stadium III (Dukes stadium C) kolonkræft (se pkt.
Capecitabine is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer (see section 5.1).
Capecitabin er kontraindiceret til patienter med svær nedsat nyrefunktion (creatininclearance under 30 ml/min ved baseline)[Cockcroft og Gault].
Capecitabine is contraindicated in patients with severe renal impairment (creatinine clearance below 30 ml/min [Cockcroft and Gault] at baseline).
Capecitabin har også været anvendt i kombination med docetaxel eller oxaliplatin til behandling af fremskreden ventrikelkræft.
Capecitabine has also been used in combination with oxaliplatin for the treatment of advanced gastric cancer.
Capecitabin kan inducere forekomsten af diarré, hvilket er observeret i op til 50 % af patienterne.
Capecitabine can induce the occurrence of diarrhoea, which has been observed in up to 50% of patients.
Capecitabin metaboliseres først af hepatisk carboxylesterase til 5’-DFCR, som derefter omdannes til 5’-DFUR af cytidindeaminase, som fortrinsvis findes i leveren og i tumorvæv.
Capecitabine is first metabolised by hepatic carboxylesterase to 5'-DFCR, which is then converted to 5'-DFUR by cytidine deaminase, principally located in the liver and tumour tissues.
Capecitabin oral to gange daglig i
Capecitabine oral twice daily for 2
Capecitabin oral to gange daglig i 2 uger (efterfulgt af 1 uge uden behandling)
2 weeks (followed by 1 week off- treatment)
Capecitabin oral to gange daglig i 2 uger (efterfulgt af 1 uge uden behandling)
Capecitabine oral twice daily for 2 weeks (followed by 1 week off- treatment)
Capecitabin SUN
Capecitabine SUN
Capecitabin SUN 150 mg er en lys ferskenfarvet filmovertrukket, bikonveks, oval tablet med mærkningen ”150” på den ene side og uden mærking på den anden side.
Capecitabine SUN 150 mg are light peach coloured, oval, biconvex, film-coated tablet debossed with ‘150’ on one side and plain on other side.
Capecitabin SUN 150 mg filmovertrukne tabletter
Capecitabine SUN 150 mg film-coated tablets
Capecitabin SUN 150 mg filmovertrukne tabletter capecitabin
Capecitabine SUN 150 mg film-coated tablets capecitabine
Capecitabin SUN 150 mg filmovertrukne tabletter.
Capecitabine SUN 150 mg film-coated tablets.
Capecitabin SUN 500 mg er en lys ferskenfarvet filmovertrukket, bikonveks, oval tablet med mærkningen ”500” på den ene side og uden mærkning på den anden side.
Capecitabine SUN 500 mg are peach coloured, oval, biconvex, film-coated tablet debossed with ’500’ on one side and plain on other side.
Capecitabin SUN 500 mg filmovertrukne tabletter
Capecitabine SUN 500 mg film-coated tablets
Capecitabin SUN 500 mg filmovertrukne tabletter capecitabin
Capecitabine SUN 500 mg film-coated tablets capecitabine
Capecitabin SUN 500 mg filmovertrukne tabletter er en ferskenfarvede 17.5 mm x 8.7 mm, bikonvekse, ovale tabletter med mærkningen ”500” på den ene side og plain på den anden side.
Capecitabine SUN 500 mg film-coated tablets are peach coloured, oval, biconvex, 17.5 mm x 8.7 mm tablets, with inscription ‘500’on one side and plain on other side.
Capecitabin SUN 500 mg filmovertrukne tabletter.
Capecitabine SUN 500 mg film-coated tablets.
Capecitabin SUN er ikke beregnet til børn eller unge.
Capecitabine SUN is not indicated in children and adolescents.
Capecitabin SUN indeholder lactose, hvor advarsel er påkrævet
Capecitabine SUN contains anhydrous lactose
Capecitabin SUN tabletter skal synkes hele med vand senest 30 minutter efter et måltid.
Capecitabine SUN tablets should be swallowed with water within 30 minutes after a meal.
Capecitabin Teva
Capecitabine Teva
Capecitabin var mindst ækvivalent med 5-FU/LV i.v. mht. sygdomsfri overlevelse i protokolpopulationen (hazard ratio 0,92; 95 % konfidensinterval 0,80-1,06).
Capecitabine was at least equivalent to IV 5-FU/LV in disease-free survival in per protocol population (hazard ratio 0.92; 95% CI 0.80 - 1.06).
Capecitabin var mindst ækvivalent med 5-FU/LV i.v. mht. sygdomsfri overlevelse i protokolpopulationen (hazard ratio 0,92; 95 % konfidensinterval 0,80-1,06).
Capecitabine was at least equivalent to IV 5-FU/LV in disease-free survival in per protocol population (hazard ratio 0.92; 95% CI 0.80-1.06).
capecitabin – 1.000 mg/m2 oralt 2 gange dagligt i 14 dage hver 3. uge i 6 serier (aften på dag 1 til morgen på dag 15 i hver serie)
capecitabine - 1000 mg/m2 orally twice daily for 14 days every 3 weeks for 6 cycles (evening of day 1 to morning of day 15 of each cycle)
Capecitabine Accord 150 mg filmovertrukne tabletter
Capecitabine Accord 150 mg film-coated tablets
Capecitabine Accord 150 mg filmovertrukne tabletter Capecitabine Accord 300 mg filmovertrukne tabletter Capecitabine Accord 500 mg filmovertrukne tabletter capecitabin
Capecitabine Accord 150 mg film-coated tablets Capecitabine Accord 300 mg film-coated tablets Capecitabine Accord 500 mg film-coated tablets capecitabine
Capecitabine Accord 150 mg filmovertrukne tabletter er lyse ferskenfarvede, aflange, bikonvekse, filmovertrukne tabletter, 11,4 mm lange og 5,3 mm brede, præget med ”150” på den ene side og jævne på den anden side.
Capecitabine Accord 150 mg film-coated tablets are light peach coloured, oblong shaped, biconvex, film-coated tablets of 11.4 mm in length and 5.3 mm in width, debossed with ‘150’ on one side and plain on other side.
Capecitabine Accord 150 mg filmovertrukne tabletter.
NAME OF THE MEDICINAL PRODUCT
Capecitabine Accord 150 mg og 500 mg filmovertrukne tabletter Tabletkerne
Capecitabine Accord 150 mg and 500 mg film-coated tablets
Capecitabine Accord 300 mg filmovertrukne tabletter er hvide til off-white, aflange, bikonvekse, filmovertrukne tabletter, 14,6 mm lange og 6,7 mm brede, præget med ”300” på den ene side og jævne på den anden side.
Capecitabine Accord 300 mg film-coated tablets are white to off white, oblong shaped, biconvex, film-coated tablets of 14.6 mm in length and 6.7 mm in width, debossed with ‘300’ on one side and plain on other side.
Capecitabine Accord 500 mg filmovertrukne tabletter
Capecitabine Accord 500 mg film-coated tablets
Capecitabine Accord 500 mg filmovertrukne tabletter er ferskenfarvede, aflange, bikonvekse, filmovertrukne tabletter, 15,9 mm lange og 8,4 mm brede, præget med ”500” på den ene side og jævne på den anden side.
Capecitabine Accord 500 mg film-coated tablets are peach coloured, oblong shaped, biconvex, film-coated tablets of 15.9 mm in length and 8.4 mm in width, debossed with ‘500’ on one side and plain on other side.
Capecitabine Accord anvendes her sammen med andre kræftmidler, bl.a. platinholdige midler som cisplatin, fremskreden eller metastatisk brystkræft (brystkræft, der er begyndt at brede sig til andre dele af kroppen).
Capecitabine Accord is used with other anticancer medicines, including a platinum-containing anticancer medicine such as cisplatin; locally advanced or metastatic breast cancer (breast cancer that has begun to spread to other parts of the body).
Capecitabine Accord anvendes her sammen med eller uden andre kræftmidler, fremskreden mavekræft.
Capecitabine Accord is used with or without other anticancer medicines; advanced gastric (stomach) cancer.
Capecitabine Accord capecitabin
Capecitabine Accord capecitabine
Capecitabine Accord er et “hybridt generisk lægemiddel”.
Capecitabine Accord is a ‘hybrid generic medicine’.
Capecitabine Accord filmovertrukne tabletter skal synkes sammen med vand inden for 30 minutter efter et måltid.
Capecitabine Accord tablets should be swallowed with water within 30 minutes after a meal.
Capecitabine Accord fås i blisterpakninger (aluminium/aluminium eller PVC/PVdC/aluminium) indeholdende 30, 60 eller 120 filmovertrukne tabletter eller i perforerede enkeltdosisblisterpakninger (PVC/PVDC/aluminium) indeholdende 30 x 1, 60 x 1 eller 120 x 1 filmovertrukne tabletter.
Capecitabine Accord is available in blister packs (Aluminium/Aluminium or PVC/PVdC/Aluminium) containing 30, 60 or 120 film-coated tablets or in perforated unit dose blister packs (PVC/PVDC/Aluminium) containing 30 x 1, 60 x 1 or 120 x 1 film-coated tablets.